• 产品名称

    参阅全部 VEGFA 一抗
  • 描述

    小鼠单克隆抗体[VG76e] to VEGFA
  • 宿主

  • 经测试应用

    适用于: ELISA, WB, IHC-Pmore details
  • 种属反应性

    与反应: Sheep, Dog, Human
    预测可用于: Mouse, Rat, Pig
  • 免疫原

    Full length protein corresponding to Human VEGFA.


    Database link: P15692-2

  • 阳性对照


Our Abpromise guarantee covers the use of ab119 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
ELISA Use at an assay dependent concentration.
WB Use at an assay dependent concentration. Detects a band of approximately 38-44 kDa.
IHC-P Use at an assay dependent concentration. Perform heat mediated antigen retrieval via the microwave method before commencing with IHC staining protocol. use Tris HCl (pH 10) and NOT citrate buffer.


  • 功能

    Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
  • 组织特异性

    Isoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed.
  • 疾病相关

    Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
  • 序列相似性

    Belongs to the PDGF/VEGF growth factor family.
  • 细胞定位

    Secreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
  • Information by UniProt
  • 数据库链接

  • 别名

    • Folliculostellate cell-derived growth factor antibody
    • Glioma-derived endothelial cell mitogen antibody
    • MGC70609 antibody
    • MVCD1 antibody
    • Vascular endothelial growth factor A antibody
    • vascular endothelial growth factor A121 antibody
    • vascular endothelial growth factor A165 antibody
    • vascular endothelial growth factor antibody
    • Vascular permeability factor antibody
    • VEGF A antibody
    • Vegf antibody
    • VEGF-A antibody
    • VEGF120 antibody
    • Vegfa antibody
    • VEGFA_HUMAN antibody
    • VPF antibody
    see all


This product has been referenced in:

  • Adeoye OO  et al. VEGF receptors mediate hypoxic remodeling of adult ovine carotid arteries. J Appl Physiol (1985) 117:777-87 (2014). Read more (PubMed: 25038104) »
  • Adeoye OO  et al. Contribution of increased VEGF receptors to hypoxic changes in fetal ovine carotid artery contractile proteins. Am J Physiol Cell Physiol 304:C656-65 (2013). Read more (PubMed: 23325408) »
See all 5 Publications for this product


1-10 of 26 Abreviews or Q&A


Thank you for contacting us.

ab2185 Immunogen sequence is more than 90% similar with Pig HIF1 alpha so this antibody is more likely to cross react.


ab21685 is anti GRP78

GRP93 there is no protein with this name. Do you think it is GRP94?

ab119 would be suitable as anti VEGF. We do have other antibodies as well but they are yet to be tested in Pig. if you are interested in testing then you may be interested in Abtrial discount programme. Please click the link for more information.


I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

Read More


Thank you for getting back in touch with me. Im afraid that I have provided you with all of the information that I have with regards this antibody. Given the information that you have obtained it is highly plausible that the non-reducing conditions are necessary for the detection of VEGF using this clone. I will certainly endevour to note this on the datasheet.

Read More


Thank you for getting back to me. That is certainly a possibility. The clones should be identical aside from individual laboratory preparation differences. Please can you tell me where you obtained this information for this clone, I am most interested in confirming the epitope information for this antibody.

Read More


Thank you for your enquiry. To our knowledge this product will cross react with VEGF165 ( J Pathol, 185: 402-408 (1998). We do not have any information regarding the product's cross reactively with other isoforms of VEGF. If you need further information, please contact us again and we will gladly assist you.

Read More


Thanks for your email. I'm replying to you on behalf of Chris, who is currently away on vacation. To use ab119 in IHC, I would recommend trying a range of dilutions in order to determine which is optimal for your particular experiment: 1:50, 1:100, 1:200. We do sell more of ab119 compared to ab3109. If you have any more questions, please let me know.

Read More


Thank you for your previous enquiry regarding the conservation of VEGF. I have been awaiting clarification of the immunogen used. The immunogen used to make the monoclonal was: the whole VEGF protein (subtype 189). The epitope that this product recognises is not known. The product is known to recognise marmoset VEGF, in vivo, and some people have reported that the product cross reacts with mouse (although the originator has never tested the product in mouse). This product has not been tested for cross reactivity with rat. I hope that this information is of use to you. If you need any further information please do not hesitate to get back in touch with me.

Read More


This goes along with the other email that I just sent you. First, ab11844 has only been tested for application in IHC. The WB listing on the datasheet was a mistake and has since been updated - I do apologize for this. Second, do you want a refund for ab119 or a different anitbody? We don't have another VEGF antibody that has been tested for cross-reactivity with pig.

Read More


Thank you for your earlier enquiry. This product will cross react with VEGF165 ( J Pathol, 185: 402-408 (1998). We do not have any information regarding the product's cross reactively with other isoforms of VEGF. If you need any further assistance please get back in touch with us.

Read More


Thank you for your email. I'm sorry to hear that ab119 did not work out for you and I can issue you a refund for this antibody - please send me the Abcam order number or purchase order number that was used when you ordered ab119. For the HIF1 alpha antibody, ab1, I'm going to require details of your protocol in order to trouble-shoot why you are experiencing problems with it. Please provide me with the lot number (located on the vial) as well as the details below. 1. Please describe the problem (high background, wrong band size, more bands, no band etc). 2. On what material are you testing the antibody in WB? •Species? •Cell extract/ Nuclear extract? •Purified protein? •Recombinant protein? 3. How much protein did you load? •How did you prepare the lysate for the analysis (protease inhibitors etc)? •Did you heat the samples? 4. Primary Antibody •Specification (in which species was it raised against)? •At what dilution(s) have you tested this antibody? •Incubation time, wash step? 5. Secondary Antibody •Specification (in which species was it raised against)? •At what dilution(s) have you tested this antibody? •Incubation time, wash step? •Do you know whether the problems you are experiencing come from the secondary? 6. What detection method are you using? 7. Background bands •Have you eliminated the possibility that any background bands could be due to the secondary antibody? (Run a “No primary” control) •Is the blocking step sufficient? (We recommend blocking the membrane by adding 20 ml of blocking buffer (5% non-fat dry milk, 0.1% Tween-20 in TBS). Incubate for 2 h at room temperature or overnight at 4°C with agitation) •Are your washing steps sufficiently stringent? (Multiple short washes are more effective than fewer longer wash steps) •At what size are the bands migrating? Could they be degradation products of your target? •Please provide an image of your blot (as an e-mail attachment, a faxed image is not sufficient) 8. Optimization attempts •How many times have you tried the Western? •Do you obtain the same results every time e.g. are background bands always in the same place? •What steps have you altered? 9. Did you apply positive and negative controls along with the samples? Please specify.

Read More

1-10 of 26 Abreviews or Q&A

For licensing inquiries, please contact partnerships@abcam.com